These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2856451)
1. [The estrogen receptor in breast carcinoma in male patients and the tamoxifen response]. Gómez Cruz P; Rivadeneyra Hinojosa J; García-Alonso H; Rábago Velasco M Ginecol Obstet Mex; 1988 Nov; 56():310-4. PubMed ID: 2856451 [No Abstract] [Full Text] [Related]
2. [Tamoxifen-induced progesterone receptors in breast tumors]. Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650 [TBL] [Abstract][Full Text] [Related]
3. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524 [TBL] [Abstract][Full Text] [Related]
5. Tamoxifen approved for node-negative breast cancer patients. Oncology (Williston Park); 1990 Aug; 4(8):15-6. PubMed ID: 2145007 [No Abstract] [Full Text] [Related]
6. Predicting response to tamoxifen in metastatic breast cancer. Connor JL; Foley JF; Lemon HM Nebr Med J; 1986 Dec; 71(12):422-6. PubMed ID: 3796760 [No Abstract] [Full Text] [Related]
7. [Radiotherapy and tamoxifen facilitate breast-preserving treatment of ductal carcinoma in situ of the breast]. Sautter-Bihl ML Strahlenther Onkol; 1999 Dec; 175(12):620-1. PubMed ID: 10633790 [No Abstract] [Full Text] [Related]
8. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
9. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946 [TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
11. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer. al-Alwan NA; al-Kubaisy W; al-Rawaq K East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039 [TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Newby JC; Johnston SR; Smith IE; Dowsett M Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in the treatment of advanced breast cancer. Clinical experience at Siriraj Hospital. Tepmongkol P; Suphaphongs N; Chantarakul N; Thansakul A J Med Assoc Thai; 1986 Feb; 69(2):96-102. PubMed ID: 3011939 [No Abstract] [Full Text] [Related]
14. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886 [TBL] [Abstract][Full Text] [Related]
15. The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study. Campbell FC; Morgan DA; Bishop HM; Benton FM; Blamey RW; Elston CW; Nicholson RI; Griffiths K Clin Oncol; 1984 Jun; 10(2):111-5. PubMed ID: 6734002 [TBL] [Abstract][Full Text] [Related]
16. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands]. Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531 [TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptors in neoplastic cells of metastatic pleural effusion of breast carcinoma before and after tamoxifen therapy. Correlation with the clinical response. Di Lorenzo D; Zaniboni A; Simoncini E; Marpicati P; Montini E; Alghisi A; Gorni F; Marini G Chemioterapia; 1986 Aug; 5(4):232-6. PubMed ID: 3769044 [TBL] [Abstract][Full Text] [Related]
20. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Roka S; Rudas M; Taucher S; Dubsky P; Bachleitner-Hofmann T; Kandioler D; Gnant M; Jakesz R Eur J Surg Oncol; 2004 Apr; 30(3):243-7. PubMed ID: 15028303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]